In summary, MBD4 deficiency increased the sensitivity of cancer cell lines to cytidine analogs (gemcitabine and cytarabine), but not to other classes of chemotherapeutic agents, including dacarbazine, commonly used in UM treatment. Here, MBD4 is linked to cancer.